Single and multiple dose pharmacokinetics of a modified-release (MR) formulation of the mGluR5 antagonist mavoglurant (AFQ056) in healthy Japanese subjects

Trial Profile

Single and multiple dose pharmacokinetics of a modified-release (MR) formulation of the mGluR5 antagonist mavoglurant (AFQ056) in healthy Japanese subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jul 2013

At a glance

  • Drugs Mavoglurant (Primary)
  • Indications Drug-induced dyskinesia; Parkinson's disease
  • Focus Pharmacokinetics
  • Most Recent Events

    • 22 Jul 2013 New trial record
    • 20 Jun 2013 Results presented at the 17th International Congress of Parkinson's Disease and Movement Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top